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Background: Patients with metabolic syndrome (MS) often have increased platelet aggregation. In order to
determine which concentration detects a higher level of platelet aggregation in patients with MS, the agonists ADP
and epinephrine were compared.
Methods: The study included 56 subjects with MS and 53 healthy subjects. Blood pressure, weight, body-mass index,
and hip-to-waist ratio were collected from all subjects. Insulin, glucose, total serum cholesterol, HDL-C, LDL-C,
total triglycerides, markers of plasma atherogenicity, and indices of insulin resistance were measured in all participants.
For aggregometry assays, the Born method was used. Platelets were treated with ADP and epinephrine in decreasing
concentrations of 2.34, 1.17, and 0.58 μM, as well as, 11.0, 1.1, and 0.55 μM, respectively. ROC curves were plotted
to define the diagnostic efficiency of epinephrine levels for MS.
Results: Among healthy individuals and MS patients significant differences were observed in body weight, body-mass
index, waist-circumference, levels of insulin, indices of insulin resistance, and levels of HDL-cholesterol, LDL-cholesterol
and total triglycerides. There was a significant difference in the detection of increased platelet aggregation using
11.0 μM and 0.55 μM epinephrine and 0.58 μM ADP. With both agonists, ROC analysis showed an area under the curve
of >0.8 for 11.0 μM epinephrine and 2.34 μM ADP. However, for MS patients, 11.0 μM epinephrine had a slightly better
diagnostic efficiency than 2.34 μM ADP.
Conclusions: It was found that 11.0 μM epinephrine and 2.34 μM ADP detected better platelet aggregation in patients
with MS than in healthy subject. Both concentrations detected increased platelet aggregation in patients with MS.
Keywords: Platelets, Metabolic syndrome, ADP, EpinephrineBackground
Increased platelet aggregation is involved in myocardial
infarction, ischemic stroke, type 1 diabetes mellitus, mi-
croangiopathy, and other diseases. For this reason, it is
important to have effective methods for identifying this
hyperactive state. Multiplate and VerifyNow are two
other very widely used point-of-care- tests however, light* Correspondence: laurapcm@prodigy.net.mx
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article, unless otherwise stated.transmission platelet aggregation (LTA), still remains the
gold standard for the study of platelet function.
Platelet factors are involved, not only in the prothrom-
botic risk associated with insulin resistance [1], but also,
in the risk associated with MS, which is related to some
prothrombotic states of increased platelet aggregation,
increased thrombin generation, and decreased fibrinoly-
sis [2].
When comparing healthy individuals with patients of
increased platelet aggregation, type 1 and type 2 diabetes
mellitus, atherosclerosis [3], ischemic coronary disease,BioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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is identified with the latter.
Diagnosis of increased platelet aggregation with LTA is
performed by adding different concentrations of agonists
to platelet rich plasma, such as: ADP, epinephrine [5], col-
lagen, collagen-related peptide, arachidonic acid, or risto-
cetin [6]. In healthy subjects, Yee DL et al. reported that
epinephrine and collagen-related peptides are reliable and
efficient agonists for the detection of increased platelet ag-
gregation [7].
The agonist epinephrine has a higher level of sensitivity
and reproducibility for detecting increased platelet aggre-
gation [3]; however, ADP is also used due to its ability to
detect possible increments in P2Y12 activity [8]. There-
fore, it is important to select the platelet agonist which is
most appropriate for a particular clinical practice. In this
study, the platelet agonists ADP and epinephrine were
compared with the aim of identifying which concentration
better detects increased platelet aggregation in patients
with MS.
Materials and methods
Subjects and design
For this case–control study, patients with MS and healthy
subjects between the ages of 25 and 75 were recruited
over a period of three years. Sample size was calculated
based on a 5% margin of error, a 95% confidence level,
and a 50% response distribution (Raosoft, Herndon, VA)
[9]. The case group had 56 MS patients, and the control
group had 53 healthy subjects. Within these two groups,
those who had taken antiplatelet or non-steroideal anti-
inflammatory drugs during a 10-day period before enter-
ing the study were excluded.
The Joint Interim Statement (JIS) has a consensus criteria
for the clinical diagnosis of metabolic syndrome [10], this is
defined as a condition displaying three or more of the fol-
lowing indicators: greater waist-circumference according to
ethnicity, ≥150 mg/dL triglycerides, < 40 mg/dL in males
and < 50 mg/dL in females with HDL-C, ≥130 mm Hg
systolic and/or ≥ 85 mm Hg diastolic blood pressure,
and >100 mg/dL fasting glucose 4 [4]. Although the JIS
does not consider insulin resistance within the criteria
for MS, it recognizes that insulin resistance is a con-
necting factor in MS. The definition of insulin resist-
ance is based on the homeostasis model assessment
(HOMA-IR) [11]. In this study, all MS patients had at
least three criteria within the JIS. In particular, waist-
circumference was considered according to the follow-
ing cutoffs: 94 cm for men and 90 cm for women [12].
Both MS patients and those in the healthy group were
screened for insulin levels, assessed by the (HOMA-IR)
[13], the quantitative insulin sensitivity check index
(QUICKI) [14], and by the lipid-parameter-based index
(Mffm/I) [15-17]. The study was approved by theInstitutional Review Board of the Graduate Program and by
the Ethics Committee of the Unidad de Bioquímica e
Inmunologia del Instituto Tecnologico Regional de Oaxaca,
México. Prior to entering the study, an agreement of writ-
ten informed consent was obtained from all participants.
Clinical and laboratory parameters
The following data was collected from all subjects: age,
weight, height, hip and waist-circumferences, and body
mass index (BMI). Height was measured with a standard
scale and weight was measured using a digital scale.
Blood pressure (BP) was evaluated on three different oc-
casions with a standard mercurial sphygmomanometer
after lying in the supine position for 5 min. In addition,
fasting glucose (Glc), total serum cholesterol (TC), HDL-
C, low density lipoprotein cholesterol (LDL-C), and TT
were measured with the Vitros DT60 II Chemistry System
(Kodak, Rochester, NY, USA). Fasting insulin was tested
with the Inmulite 1000 Immunoassay Analyzer (Diagnostic
Products Corporation, Llanberis Glyn Rhonwy Caernarfon,
UK).
Platelet aggregation test
Blood was drawn from 53 healthy subjects and 56 patients
with MS. First, it was diluted in a solution of 3.8% sodium
citrate and centrifuged at 150 g, at room temperature for
15 min. Platelet-rich plasma (PRP) was removed with
silicone-coated Pasteur pipettes and stored in plastic test-
tubes at room temperature for a maximum of 180 min.
Adenosine 5′-disphosphate (ADP) and epinephrine bitar-
trate were obtained from Sigma (Sigma Chemical Co., St.
Louis, MO, USA). Various agonist concentrations were se-
lected to identify possible differences within the groups.
Concentrations of 2.34, 1.17, and 0.58 μM ADP and 11.0,
1.1, and 0.55 μM epinephrine were evaluated. LTA assays
were performed on these agonist concentrations using a
dual-channel platelet aggregometer (Sienco, Houston, TX,
USA) based on the Born method [18]. Platelet counts of
the PRP were standardized at 200 × 109/L with autologous
platelet-poor plasma. The incubation time was 1 min at
37°C. A stirring rate of 1,200 rpm and a running time of
6 min were maintained after adding 15 μL of the respect-
ive ADP and epinephrine concentrations.
Calculations
The insulin sensitivity index, derived from fasting mea-
surements of the HOMA-IR, QUICKI, and Mffm/I, gave
an appropriate calculation of insulin resistance, which was
calculated as previously described [6-8]. The Atherogenic
index of plasma (AIP), a sensitive marker of differences in
lipoprotein complex, increased significantly with greater
atherogenic risk, this AIP was calculated as reported by
Dobiásová [19].
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In consideration of the variability in factors occuring in
subjects with insulin resistance, an attempt was made to
select subjects with clinical characteristics as similar as
possible. The Unpaired t test with Welch's correction was
performed to detect differences in the median using the
GraphPad Prism version 3.0 of Windows (GraphPad Soft-
ware, San Diego, CA, USA). The p value < 0.05 was consid-
ered statistically significant, and the Receiver Operating
Characteristic curve was plotted using the GraphPad Prism
version 6.00 of Windows, GraphPad Software, La Jolla
California USA, www.graphpad.com.Results
The groups evaluated in this study consisted of 53 healthy
and 56 MS subjects. Amongst the two groups, significant
differences were observed in terms of body weight,
BMI, and waist-circumference. Additionally, significant
differences were found in levels of HDL-C, LDL-C, TT,
insulin, and AIP, HOMA IR, QUICKI, and Mffm/I indi-
ces (Table 1). This suggests that patients from the MSTable 1 Demographic and biochemical characteristics of the s
Healthy individuals
(n = 53)
Age (years) 63.0 ± 13.5
Weight (kg) 65.5 ± 13.0
SBP (mmHg) 121 ± 22.7
DBP (mmHg) 70 ± 7.9
BMI (kg/m2) 24.0 ± 1.98
Waist-circumference (cm)
Men 85 ± 4.2
Women 75 ± 6.4
Fasting glucose (mg/dL) 87.8 ± 7.79
AIP 0.38 ± 0.17
Insulin (μU/mL) 7.35 ± 3.08
HOMA-IR 1.57 ± 0.64
QUICKI 0.36 ± 0.02
Mffm/I 6.83 ± 1.18
TC (mg/dL) 232 ± 176
HDL-C (mg/dL)
Men 47.5 ± 5.2
Women 58.3 ± 6.5
LDL-C (mg/dL) 106.40 ± 46.70
TT (mg/dL) 170.00 ± 45.00
SBP systolic blood pressure, DBP dyastolic blood pressure, BMI body mass index, Hb
homeostatic model assessment, QUICKI quantitative insulin sensitivity check index,
cholesterol, LDL-C LDL-cholesterol, TT total triglycerides, MS metabolic syndrome. A
analysed using Unpaired t test with Welch's correction.group are overweight, insulin resistant and have an in-
creased atherogenic risk.
In relation to platelet aggregometry assays, an increase
in platelet aggregation was found in healthy subjects
with the addition of 1.17 μM ADP, and 1.1 μM Epineph-
rine. In MS patients, concentrations of 0.58 μM ADP,
11.0 and 0.55 μM epinephrine were increased (Table 2).
The ROC curve was used in order to differentiate be-
tween healthy subjects and patients with MS and to com-
pare the effects of the concentrations of epinephrine and
ADP. The area under the curve (AUC) is generally consid-
ered acceptable when >0.8 [20]. This study showed an
AUC >0.8% for epinephrine and ADP concentrations of
11.0 and 2.34 μM, respectively (Figure 1).
Three different concentrations of agonists in ROC
analysis of platelet aggregometry revealed that one, had
a cut-off of > 57.0%, a sensitivity of 80.00%, and a specifi-
city of 75.86% with 11.0 μM epinephrine, another, had a
cut-off of <30.75%, a sensitivity of 60.00%, and a specifi-
city of 89.66% with 1.1 μM epinephrine, and the other,
had a cut-off of > 24.50%, a sensitivity of 33.33% and a
specificity of 96.55% with 0.55 μM epinephrine. Thesetudy population
Patients with MS P
(n = 56)
61 ± 16.0 0.4813
80 ± 27.0 < 0.0001
123 ± 40.0 0.7473
70 ± 10.0 1.0000
27.0 ± 4.01 <0.0001
105 ± 10.4 <0.0001
92 ± 5.7 <0.0001
88.8 ± 10.13 0.5635
0.66 ± 0.26 < 0.0001
9.78 ± 3.50 < 0.0002
1.85 ± 0.78 0.0425
1.13 ± 1.79 < 0.0022
5.11 ± 0.89 < 0.0001
198 ± 62 0.1881
35.6 ± 16.2 <0.0001
36.1 ± 20.1 <0.0001
130.00 ± 60.60 0.0244
286.00 ± 155.50 < 0.0001
hemoglobin, Ht hematocrit, AIP atherogenic index of plasma, HOMA-IR
Mffm/I lipid-parameter-based index, TC total serum cholesterol, HDL-C HDL-
ll values were presented as mean ± SD. Differences between the groups were
Table 2 Results of platelet aggregometry assays
Healthy individuals Patients with MS% P
(n = 53) (n = 56)
ADP 2.34 μM 61.4 ± 11.7 59.2 ± 8.9 0.2739
ADP 1.17 μM 53.8 ± 12.3 32.4 ± 19.9 0.0001*
ADP 0.58 μM 38.5 ± 8.85 43.5 ± 7.2 0.0017*
Epinephrine 11.0 μM 47.4 ± 15.0 84.0 ± 30.8 <0.0001*
Epinephrine 1.1 μM 36.4 ± 15.2 14.8 ± 17.3 <0.0001*
Epinephrine 0.55 μM 17.4 ± 4.7 26.8 ± 7.7 <0.0001*
ADP adenosine diphosphate, MS metabolic syndrome. All values are presented as mean ± SD. Differences between groups were estimated using a Unpaired t test
with Welch's correction. *statistically significant.
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MS subjects.
ROC analysis of ADP revealed that a platelet aggrega-
tion cut-off of > 58.15% had a sensitivity of 76.36%, and a
specificity of 82.76% with 2.34 μM. A cut-off of <30.75%
had a sensitivity of 50.00%, and specificity of 89.00% with
1.17 μM, and an inverse cut-off of < 30.25% had a sensitiv-
ity of 5.55% and a specificity of 93.10% with 0.58 μM
ADP. These analyses also showed differences between
healthy and MS subjects.Figure 1 Receiver operating characteristic curves derived from platele
A. Epinephrine 11.0 μM. B. Epinephrine 1.10 μM. C. Epinephrine 0.55 μM; DDiscussion
Since increased platelet aggregation is related to athero-
thrombotic risk, it is important to identify subjects with
persistent hyperfunctional platelets [21]. ADP is one of the
most important platelet agonists. ADP is a nucleotide able
to activate three different subtypes of receptors namely,
P2Y1, P2Y12, and P2Y13 [22]. These receptors are also in-
vitro concentration dependent. For example, ADP concen-
trations of between 10 and 20 μM may cause TxA2-inde-
pendent aggregation while a moderate concentration oft aggregometry assays from healthy individuals and MS patients.
. ADP 2.34 μM. E. ADP 1.17 μM. F. ADP 0.58 μM.
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over, in order to initiate the agonist effect of ADP, co-
activation of P2Y1 and P2Y12 is required. In this study, a
low concentration of ADP was also used.
Noteworthy, is an increased response in platelet aggre-
gation, elicited by ADP assays, due to a P2Y12 receptor
gene H2 haplotype. This is also able to increase the risk
of coronary artery disease [24]. Also, signaling, through
the P2Y12 receptor, enhances platelet reactivity, due to
hypercholesterolemia [25].
It appears that ADP and epinephrine are weak agonists
in platelet aggregation, in contrast to thrombin and col-
lagen, which are used as agonists in other methods to
identify platelet hyperactivity associated with polymor-
phisms, such as, GPIIIa PlA1 allele, in the case of Colla-
gen/Epinephrine closure time (CEPI-CT) [26].
Platelet hyperactivity in LTA with epinephrine is asso-
ciated with ageing men [27], and also in patients with
non-insulin-dependent diabetes mellitus (NIDDM). It is
attributed to enhanced platelet aggregation in the pres-
ence of a thrombin receptor-activating peptide or epi-
nephrine [28], and noted in studies in patients with
ischemic heart disease, by Yokoyama M et al. [29]. The
latter found that ADP and epinephrine had variable re-
sponses from person to person, using a range of concen-
trations from 100 to 0.1 μM, and an increased platelet
sensitivity to adrenaline in subjects of advanced age. Epi-
nephrine is also related to a variant of angina, which is
detected by less agonist activity and relates to concentra-
tions used in this study [30].
In this study, 11.0 μM epinephrine gave a ROC curve
area of 0.8526, which suggests that this may differentiate
better between healthy subjects and patients with MS.
Moreover, 2.34 μM ADP gave a slightly larger area under
a curve of 0.8671. Lesser doses of 0.55 μM ADP were
not able to identify MS patients correctly, although
shown as significant in Unpaired t tests with Welch's
corrections (Table 2).
When comparing the ROC curves of 2.34 μM ADP
and 11.0 μM epinephrine, although the area of the curve
was greater in ADP, the epinephrine curve climbed
quickly toward the top-left. This suggests that the
11.0 μM concentration may be better in identifying pa-
tients with increases in platelet aggregation. However, in
consideration of the fact that both agonists provide in-
formation related to different signaling pathways, both
concentrations may be useful in the study of MS.
Obesity and MS are strong predictors of coronary
heart disease, in addition to the use of the AIP [31]. In
the MS group there was an increase in the AIP. As a
consequence, one may come to the conclusion that the
group with MS also had an increased atherogenic risk
and a higher risk of developing type 2 diabetes and vas-
cular conditions when compared to the healthy group.Moreover, individuals with high total triglycerides have
greater AIP levels and an increased atherogenic risk. In
the MS group, hypertriglyceridemia, with reduced HDL-
C and increased LDL-C, is associated with the athero-
genic triad, and may be related to increased platelet ag-
gregation, leading to an increased atherothrombotic risk
[32,33].
In this study, 44 patients in the MS group were women.
They had an waist-circumference increased, which suggests
that, although not all patients with obesity have insulin re-
sistance, they may have increased platelet aggregation as a
consequence of the negative effects of visceral obesity [34].
Moreover, the anti-aggregating effect of insulin is lost on
patients with insulin resistance as it can occur in obesity,
diabetes mellitus, arterial hypertension [35], or in MS. In
the MS group, despite having an increase in insulin, its ef-
fect on platelets was reduced.
The HOMA-IR, QUICKI, and Mffm/I indices are based
on fasting levels of insulin and glucose. All indices in the
MS group differed significantly, compared to those ob-
tained in healthy subjects. These indices were an evaluation
of hepatic insulin resistance (IR), rather than peripheral in-
sulin sensitivity. Hepatic IR is a major contributing factor
in pre-diabetic states and it is also related to impaired fast-
ing glucose levels [36]. However, it is not totally proven if
platelet insulin resistance is due, solely, to obesity [14,37].
In this study, all the MS patients had an increased weight
and obesity, which may indicate that these patients have
platelet insulin resistance.
This study has some limitations and caution should be
taken in the interpretation of the findings because of the
small sample size of the study. Additionally, it may be
possible that other platelet agonists, such as serotonin
and submaximal doses of epinephrine induce platelet ag-
gregation and they could be considered in further ana-
lysis [38].
This study supports the use of these agonist concen-
trations to perform platelet aggregation assays, as they
could improve identification of increased platelet aggre-
gation in patients with MS.
Conclusion
We found an increase in platelet aggregation in subjects
with MS when platelet aggregation assays were per-
formed using 11.0 μM epinephrine and 2.34 μM ADP.
These tests showed an area under the ROC curve which
distinguishes between patients with MS and healthy sub-
jects with increased platelet aggregation.
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